The role of TNF-\(\alpha\) inhibitor in glioma virotherapy: a mathematical model
From MaRDI portal
Publication:335279
DOI10.3934/mbe.2017020zbMath1362.92034OpenAlexW2531096805WikidataQ40438792 ScholiaQ40438792MaRDI QIDQ335279
Avner Friedman, Maciej Leszczynski, Elzbieta Ratajczyk, Urszula Łedzewicz-Kowalewska
Publication date: 2 November 2016
Published in: Mathematical Biosciences and Engineering (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.3934/mbe.2017020
Related Items (4)
Treatment of glioma with virotherapy and TNF-\(\alpha\) inhibitors: analysis as a dynamical system ⋮ Analysis of a delayed and diffusive oncolytic M1 virotherapy model with immune response ⋮ Optimal control for a mathematical model of glioma treatment with oncolytic therapy and TNF-\(\alpha \) inhibitors ⋮ Multiscale modelling of cancer response to oncolytic viral therapy
Cites Work
- Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response
- Modeling and analysis of a virus that replicates selectively in tumor cells
- Effects of CCN1 and macrophage content on glioma virotherapy: a mathematical model
- Optimal control for mathematical models of cancer therapies. An application of geometric methods
- Mathematical model of sarcoidosis
This page was built for publication: The role of TNF-\(\alpha\) inhibitor in glioma virotherapy: a mathematical model